Bispecific antibodies that redirect the lytic activity of cytotoxic immune effector cells, such as T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated treatment modality for hematological malignancies. Advancement of this therapeutic concept into solid tumor indications, however, is hampered by the scarcity of targetable antigens that are surface-expressed on tumor cells but demonstrate only limited expression on healthy tissues. To overcome this limitation, the concept of dual-targeting, i.e. the simultaneous targeting of two tumor-expressed surface antigens with limited co-expression on non-malignant cells, with multispecific antibodies has been proposed to increase tumor selectivity of antibody-induced effector cell cytotoxicity. Here, a novel CD16A (FcγRIIIa)-directed trispecific, tetravalent antibody format, termed aTriFlex, is described, that is capable of redirecting NK cell cytotoxicity to two surfaceexpressed antigens. Using a BCMA/CD200-based in vitro model system, the potential use of aTriFlex antibodies for dual-targeting and selective induction of NK cell-mediated target cell lysis was investigated. Bivalent bispecific target cell binding was found to result in significant avidity gains and up to 17-fold increased in vitro potency. These data suggest trispecific aTriFlex antibodies may support dual-targeting strategies to redirect NK cell cytotoxicity with increased selectivity to enable targeting of solid tumor antigens.
Introduction
Recombinant antibody technology has spawned a plethora of antibody formats in recent years that have enabled the rapid development and introduction of novel immunotherapeutic approaches to cancer treatment. Among these, redirecting immune effector cell lysis to tumors using bispecific antibodies has received significant attention due to its high potency and demonstrated clinical efficacy (Linke et al., 2010; Garber, 2014; Topp et al., 2014) . T cells and natural killer (NK) cells are the most commonly used effector cell populations to effect direct tumor lysis as both share a similar mechanism of action that results in rapid and efficacious target cell death. Following target cell binding using one antibody specificity, effector cell cytotoxicity is stimulated through antibody interaction with activating receptors CD3ε or CD16A (FcγRIIIa) on T or NK cells, respectively (Fanger et al., 1990) . Target cell interaction and receptor stimulation induce the formation of an immunological synapse, polarized exocytosis of lytic granules containing perforin and granzymes, and surface expression of FasL, TRAIL and TNF-α, which specifically induces target cell apoptosis (Topham and Hewitt, 2009) .
While the potency of this approach to bring about direct target cell lysis is well established and has been clinically validated (Klinger et al., 2012; Tsikouras et al., 2013; Rothe et al., 2015) , development of bispecific antibodies to engage cytotoxic effector cells has been largely limited to hematological malignancies due to the scarcity of targetable surface antigens in solid tumor indications. Although a small number of clinical trials of bispecific antibodies targeting antigens expressed in advanced solid tumors, such as EpCAM, CEA and PSMA, were initiated, there are major concerns over the potential risk of effector cell activation in healthy organs due to low level target expression (Huehls et al., 2015) . Such 'on-target/off-tumor' activity in pulmonary tissue is seen as the likely explanation for the death of a patient treated for metastatic HER-2/neu-positive colon cancer in the context of a clinical trial with HER-2/neu-directed chimeric antigen receptor T cells (Morgan et al., 2010) . While this patients' death was ultimately caused by a rapid onset of T cellmediated cytokine storm, direct lysis of target-positive cells can result in damage to healthy organs, which presumably halted development of an EGFR-targeted T cell engaging bispecific (Lutterbuese et al., 2010) . These findings highlight the challenge of safely retargeting effector cells to tumors in the absence of antigens with true tumor-restricted tissue expression. It should be said that in comparison NK cell activation is not associated with systemic symptoms of high-level cytokine release as frequently seen with T cell-based approaches and is hence considered a potent immunotherapeutic strategy with reduced toxicity (Brentjens et al., 2010; Morgan et al., 2010; Klinger et al., 2012; Rothe et al., 2015; Shah et al., 2015; Romee et al., 2016) . However, T and NK cells share an almost identical mechanism of direct cell killing, hence 'off-tumor' NK cell activation should be avoided to prevent toxicities. Consequently, there is a need for alternative strategies that do not rely on the availability of single targetable antigen to safely redirect NK cell lysis and overcome limitations of current approaches.
The simultaneous targeting of two tumor-expressed antigens, referred to here as 'dual-targeting', has been proposed as a strategy to increase antibody selectivity for tumor cells because of the potential gain in avidity upon bivalent target interaction relative to monovalent binding. As selectivity of such approaches is not determined by expression of a single target antigen but co-expression of two antigens at a level sufficient for bivalent binding, dual-targeting may expand the available target space for effector cell-engaging antibodies.
In this study, we describe the development of a novel trispecific antibody format to selectively redirect NK cell cytotoxicity via CD16A engagement and dual-targeting. By definition, this requires an antibody format that can incorporate three specificities and is therefore at least trivalent. We have previously described the development of a first-in-class tetravalent CD30/CD16A-directed bispecific tandem diabody (TandAb), AFM13, currently in active clinical development to treat CD30+ Hodgkin lymphoma (Reiners et al., 2013; Reusch et al., 2014; Rothe et al., 2015) . AFM13 incorporates two variable fragments (Fv) of a CD30-specific antibody and two Fv of a high-affinity CD16A-selective antibody (LSIV21). Bivalency for CD16A results in high avidity NK cell interaction and superior in vitro activity when compared with classical and Fc-engineered CD30-targeting monoclonal antibodies (Reusch et al., 2014) . We have previously also described a tetravalent antibody format, termed Flexibody, that resembles TandAbs in its overall composition and use of a diabody structure to mediate homodimerization and NK cell binding but incorporates target specificities as single chain (sc) Fv in distal positions connected to a central diabody motif by a flexible peptide linker ( Fig. 1) (Le Gall et al., 2003) . It was hypothesized that this format may be particularly suited for the development of a dual-targeting NK cell engager as it retains bivalency for CD16A but allows greater structural flexibility to achieve bivalent target binding than the TandAb format. To explore the feasibility of dualtargeting, the multiple myeloma (MM)-expressed target antigens B cell maturation antigen (BCMA, CD269) and CD200 were chosen because of the availability of low affinity scFv antibodies against these targets from previous and ongoing programs. BCMA is considered a highly attractive target antigen for immunotherapy of MM and a well-manageable safety profile of BCMA-targeting approaches has been well established (Ali et al., 2016) . However, when this study was initiated reports of low level expression of BCMA on human keratinocytes also suggested a potential rationale for dualtargeting of BCMA and CD200 to increase selectivity for coexpressing MM cells (Alexaki et al., 2012) . Using an in vitro model system based on these targets we demonstrate that trispecific antibodies of the newly developed 'aTriFlex' format exhibit increased selectivity of target cell binding and subsequent NK cell cytotoxicity towards target antigen co-expressing cells suggesting the feasibility of dual-targeting in future developments, including in currently difficult to target solid tumors.
Materials and methods

Plasmid construction
Expression plasmids encoding recombinant antibodies and soluble antigens were generated by subcloning coding sequences into the mammalian expression vector pCDNA5/FRT (ThermoFisher Scientific) using standard molecular biology techniques. Constructs encoding anti-CD16A single-chain variable fragment (anti-CD16A scFv) and anti-CD16A diabody (Db) were generated by ligating sequences encoding light chain (VL) and heavy chain (VH) variable domains of the CD16A-specific antibody LSIV21 (Reusch et al., 2014) in VL-VH arrangement incorporating (GGS) 6 (scFv) or (GGS) 2 (diabody) linker sequences and a C-terminal hexahistidine tag (6xHis). Recombinant soluble CD16A, BCMA and CD200 were expressed from vectors encoding the extracellular domain of human CD16A (UniProtKB P08637, residues 17-208), human BCMA (UniProtKB Q02223, residues 1-54) and human CD200 (UniProtKB P41217, residues 31-232) fused to monomeric human Fc (mFc.67), as described by Ying et al. (2012) . For surface antigen expression on stably transfected CHO cells, human BCMA(1-54) (UniProtKB Q02223, residues 1-54) was expressed as a C-terminal fusion protein with human CD3ζ (UniProtKB P20963, residues 31-164). Human CD200 was expressed as the full-length protein (UniProtKB P41217). Cells co-expressing both antigens were generated by transfection with a modified bicistronic pCDNA5/FRT plasmid containing two expression cassettes. Heterodimeric anti-CD16A diabody (ncDb) in non-classical domain arrangement was expressed from two genes, encoding chain A (VL CD16A -(GGS) 3 -VL CD16A -6xHis) and
-FLAG), subcloned into the bicistronic pCDNA5/FRT vector. For the generation of constructs encoding trispecific aTriFlex antibodies, sequences encoding anti-BCMA scFv and anti-CD200 scFv were subcloned into the gene encoding chain A of ncDb resulting in VH BCMA -(GGS) 6 -VL BCMA -
-(GGS) 6 -VL CD200 -6xHis. All constructs, except those encoding cell surface-expressed CD200, were designed to encode the N-terminal signal peptide MERHWIFLLLLSVTAGVHS to effect protein secretion or membrane translocation. Coding sequences of all constructs were synthesized by GeneArt Gene Synthesis (ThermoFisher Scientific) and final expression plasmids were verified by DNA sequencing. FCS and 100 μg/ml Zeocin. Adherent cells were detached with 0.25% Trypsin-EDTA and subcultured according to standard cell culture protocols provided by Life Technologies. For adaptation to growth in suspension, cells were detached from tissue culture flasks and placed in serum-free HyClone CDM4 CHO (GE Healthcare) medium supplemented with L-glutamine, HT supplement, Penicillin/ Streptomycin and 100 μg/ml Zeocin for subsequent incubation in shake flasks at 37°C, 5% CO 2 and 120-140 rpm. Suspensionadapted cells were cryopreserved in medium with 10% DMSO and tested negative for Mycoplasma using MycoAlert Mycoplasma detection Kit (Lonza).
Cell lines and cell culture
Protein expression and purification
Stable, recombinant protein-expressing cells were generated and used for expression of recombinant protein expression as previously described (Reusch et al., 2016) . Recombinant human CD16A-mFc.67 antigen was purified by protein A affinity chromatography. For this, clarified cell culture supernatant was loaded on a 5 ml MabSelect™ SuRe™ column (GE Life Science) and washed with PBS and 10 mM sodium phosphate (pH 7.0). Bound protein was eluted with 10 mM sodium acetate, pH 3.5, and eluates were neutralized with 1 M Tris/ HCl (pH 8.8). 6xHis-tagged proteins were purified by immobilized metal affinity chromatography (IMAC) using a 5 ml HisTrap FF column linked to an Äkta purifier. Protein elution was monitored at 280 nm wavelength. Following washing with Tris/NaCl buffer (pH 7.5), bound protein was eluted stepwise with 15 mM, 125 mM and 500 mM imidazole, respectively. Purity of collected fractions of protein A chromatography or IMAC eluates was analyzed by SE-HPLC and SDS-PAGE, as described below. Fractions containing the desired molecular species were pooled and further purified by preparative SEC (pSEC) using a Hiload™ 26/600 or Hiload™ 16/600 Superdex 200 prep-grade column, equilibrated with 30 mM sodium phosphate and 750 mM arginine (pH 6.0). Protein elution during all steps was monitored at 280 nm; fractions were collected and analyzed again by SE-HPLC and SDS-PAGE. SE-HPLC was performed by resolving protein samples at 0.5 ml/min on a Superdex 200 10/300 GL column (GE Life Sciences), equilibrated with 30 mM sodium phosphate, 750 mM arginine (pH 6.0), linked to a Dionex Ultimate 3000 system (Thermo Scientific). Comparison of elution volumes with molecular weight marker proteins (Ribunuclease A: 13.7 kDa; Ovalbumin: 43.0 kDa; Aldolase: 158 kDa; Ferritin: 440 kDa; GE Life Sciences) was used to estimate the apparent molecular weights. Data analysis was performed using the Chromeleon software (Thermo Scientific). SDS-PAGE was performed by subjecting proteins to protein gel electrophoresis at 300 V using Criterion™ TGX Stain-Free™ Precast Gels 4-20% (Bio-Rad), following heating of samples in SDS-sample buffer (0.2 M DTT) for 5 min at 85°C. Product integrity in cell culture supernatants and protein expression titers were determined by Stain-free gel imaging (Kazmin et al., 2002) . Band intensities were normalized by Tryptophan content and converted to molar concentrations using the theoretical molecular weight and comparison with known protein standards. For estimation of molecular weights, Page Ruler™ Unstained (#26614) and Prestained (#26619) Protein Ladder (Thermo Scientific) were used. Protein was visualized by stain-free gel imaging technology (Gel Doc EZ Imager, Bio-Rad). Fractions containing the molecular species of interest were pooled and dialyzed against sodium acetate buffer pH 5.0 for subsequent concentration tõ 1 mg/ml by ultrafiltration. Protein concentration was determined by standard methods (Wilkins et al., 1999) before storage at −80°C until further use.
Analysis of protein stability
Temperature-induced unfolding of purified recombinant proteins was measured by differential scanning fluorimetry (DSF) on a Rotor-Gene Q (Qiagen) applying a temperature gradient of 1°C/ min. Melting temperatures were obtained by recording temperatureinduced changes in Sypro Orange fluorescence (610 nm) and were defined as the midpoint of the first observed protein unfolding transition. To assess protein stability at 2-8°C and 40°C, samples were adjusted to 0.5 mg/ml in 10 mM sodium acetate buffer (pH 5.0) and incubated for up to 7 days followed by SDS-PAGE and SE-HPLC.
SPR analyses
Interaction kinetics of antibody binding to recombinant antigen were measured using a Biacore T200 System (GE Healthcare) at 25°C in HBS-P+ running buffer (GE Healthcare). Antibodies were captured using the His Capture Kit (GE Healthcare) immobilized on a C1 sensor chip using capture levels of 20 RU. Recombinant antigens were injected at a flow rate of 30 μl/min for 180 s, followed by dissociation for 300 s. Data were captured in two flow cells and were double referenced against zero concentration samples. Sensor chips were regenerated using 10 mM glycine (pH1.5) for 30 s at 10 μl/min. Data were fitted to a 1:1 binding model using Biacore Evaluation Software.
Flow cytometry
Analysis of anti-CD16A and aTriFlex antibody binding to cells was performed by incubating cells with serially diluted antibody in FACS buffer (PBS, Invitrogen, catalog number 14190-169) containing 2% heat-inactivated FCS (Invitrogen, catalog number 10270-106) and 0.1% sodium azide (Roth, Karlsruhe, Germany, catalog number A1430.0100) for 45 min as indicated at 37°C. To measure antibody binding to NK cells, samples were supplemented with 1 mg/ml polyclonal human IgG (Gammanorm, Octapharma, Langenfeld, Germany, catalog number PZN-2451445) to block binding of antibodies to Fcγ receptors. After repeated washing with FACS buffer, cell-bound antibodies were detected with 10 μg/ml mAb anti-His clone 13/45/31-2 (Dianova, Hamburg, Germany, catalog number DIA910-1MG) followed by 15 μg/lFITC-conjugated goat anti-mouse IgG (Dianova, Hamburg, Germany, catalog number 115-095-062). Following further washing, cells were resuspended in 0.lf FACS buffer containing 2 μg/ml propidium iodide (PI) (Sigma, catalog number P4170) to exclude dead cells. The fluorescence of 2-5 × 10 3 living cells was measured using a BeckmanCoulter FC500 MPL flow cytometer using the MXP software (Beckman-Coulter, Krefeld, Germany) or a Millipore Guava EasyCyte flow cytometer (Merck Millipore, Schwalbach, Germany). Mean fluorescence intensities (MFI) of the cell samples were calculated using CXP software (Beckman-Coulter) or Incyte software (Merck Millipore, Schwalbach, Germany) following subtraction of MFI values of control samples. Equilibrium dissociation constants (K D ) were calculated using the one-site-binding (hyperbolic) fit and GraphPad Prism software (GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla, CA). Surface expression of BCMA and CD200 antigens was quantified by QIFIKIT analysis (Dako, catalog number K0078) using anti-BCMA mAb ANC3B1 (Ancell, catalog number 269-020), and anti-CD200 mAb MRC OX-104 (BD Pharmingen, catalog number 552023) according to the manufacturer's instructions. In brief, aliquots of 1 × 10 6 cells were stained with 10 μg/ml mAb ANC3B1 or mAb MRC OX-104 followed by F(ab′) 2 fragment of FITCconjugate goat anti-mouse IgG. As negative control, aliquots of 1 × 10 6 cells were stained with 10 μg/ml anti-c-myc mAb 9E10 (Acris, catalog number SM1863P) followed by F(ab′) 2 fragment of FITCconjugate goat anti-mouse IgG. To calculate the specific antibody binding capacity (SABC), MFI values were compared with a calibration curve obtained from staining of reference beads with F(ab′) 2 fragment of FITC-conjugate goat anti-mouse IgG. These experiments were performed at least three times to quantify surface expression of BCMA and CD200 on the generated CHO cell lines.
In vitro cytotoxicity assays
Peripheral blood mononuclear cells (PBMC) were isolated from healthy volunteers' buffy coats (German Red Cross, Mannheim, Germany) by density gradient centrifugation using Lymphoprep (StemCell Technologies, Inc., catalog number 07861), as described (Fuss et al., 2009 NK cell activation and quantification of IFN-γ release NK cell activation was assessed by quantifying CD69 surface expression on primary human NK cells by flow cytometry following incubation with stably transfected BCMA, CD200 or BCMA/ CD200-expressing CHO cells or untransfected cells (1 × 10 4 cells/ well) for 21 h at an E:T ratio of 5:1 in presence of increasing antibody concentrations. The percentage of CD69+ cells within the CD56 + population was determined using CXP software (BeckmanCoulter) and plotted using GraphPad Prism software. IFN-γ release was quantified using the Human IFN-gamma ELISA (RayBiotech) according to manufacturer protocols using 1:2 diluted cell culture supernatants. IFN-γ concentrations were interpolated and plotted using GraphPad Prism.
Results
Engineering of an anti-CD16A diabody-like core module to enforce antibody heterodimerization
Flexibodies are bispecific, tetravalent antibodies in which the functional homodimer is formed by interchain association of a central bivalent anti-CD16A diabody motif (Fig. 1A) . Development of an antibody format capable of dual-targeting of tumor cells and NK cell engagement via CD16A requires replacement of one scFv antibody targeting a tumor-expressed antigen with that of a second specificity resulting in a heterodimeric design. Consequently, a strategy was needed to ensure assembly of the correctly heterodimerized antibody and to reduce the amount of homodimeric side-products that would not exhibit dual-targeting properties. To this end, it was tested whether the central diabody motif could be redesigned to prevent homodimer formation by redistributng VL and VH chains of the constituting anti-CD16A LSIV21 Fv domains onto different polypeptides. To test this idea, two diabody modules were generated incorporating VL and VH chains in either classical (VH-VL) or non-classical (VH-VH × VL-VL) domain order, resulting in the formation of homodimeric (Db) and heterodimeric (ncDb) anti-CD16A diabody, respectively (Fig. 1B) . Both proteins could be readily expressed in stably transfected CHO cell lines and could be purified to homogeneity in a single step by affinity chromatography (Fig. 1C) . Subjecting cell culture supernatant to SDS-PAGE followed by relative quantification of band intensities suggested that the two chains of the heterodimeric ncDb were produced in near equimolar amounts ( Supplementary Fig. 1A available at PEDS online). SEC analysis of IMAC-captured diabodies from cell culture supernatants suggested that Db and ncDb almost exclusively formed dimeric complexes of the desired molecular mass with negligible side-products, respectively ( Fig. 2A and Table I ). Molecular mass and total protein concentration were unchanged when both antibodies were incubated at 2-8°C and 40°C for up to 7 days ( Fig. 2A) or subjected to three rounds of freezing and thawing (Fig. 2B) . Similarly, monitoring thermal unfolding by DSF did not reveal significant differences between Db and ncDb with melting temperatures (T m ) of 62.5°C and 63°C, respectively (Fig. 2C ). These data suggest that redistribution of VL and VH chains did not negatively affect producibility or stability of the anti-CD16A diabody-like module and may be suited to enforce heterodimerization of polypeptide chains in a Flexbody-like trispecific format. Binding affinities of the produced antibodies were tested next to assess the impact of domain rearrangement on intrinsic affinities and functional bivalency for CD16A. First, monovalent interaction kinetics of Db and ncDb binding to recombinant, monomeric human CD16A-mFc.67 were determined by SPR analysis and compared with anti-CD16A scFv (Fig. 3A-C) . Equilibrium dissociation constants (K D ) were comparable between all antibodies tested (25-29 nM) suggesting no impact of the antibody format on intrinsic binding affinities. Functional bivalency was subsequently confirmed by titrating antibodies on primary human NK cells. Bivalent Db and ncDb exhibited apparent cell binding affinities (K D ) of 2.8 nM and 7.7 nM that were markedly higher than that of monovalent anti-CD16A (47.3 nM) (Fig. 3D) suggesting activity of both paratopes. However, the observed reduction of cell binding affinity of ncDb suggested structural differences relative to Db that, to a minor degree, restrict its ability to bind bivalently.
Generation of trispecific aTriFlex antibodies
It was next tested whether further specificities may be added to the diabody-like domain arrangement in ncDb to generate a heterodimeric, tetravalent antibody. For this, Fv domains specific for BCMA and CD200 isolated from human naïve human antibody libraries by phage display (data not shown) and fused to the N-and C-terminus of the anti-CD16A VL-containing chain, resulting in an asymmetric, trispecific Flexibody (aTriFlex) comprised of two differently sized chains (Fig. 4A) . This arrangement was chosen to facilitate purification and simplify downstream detection of undesired homodimerized by-products based on different SEC elution volumes. To limit NK cell activation upon monovalent target cell interaction, antibodies with low affinity target binding, as determined by SPR analysis (Table II) , were selected and incorporated into the aTriFlex format. A set of three aTriFlex antibodies was generated, expressed in CHO cells and production of both antibody chains in cell culture supernatants was quantified (Table III and Supplementary Fig. 1B available at PEDS online) . This analysis suggested near equimolar production of the two antibody chains of aTriFlex_113 and aTriFlex_115 and an expression titer of >200 mg/l, which was comparable with ncDb. SEC analysis of IMAC-purified protein further suggested that the two constituting chains of aTriFlex_113 and aTriFlex_115 efficiently assembled into heterodimers with product contents of 87.0% and 93.1%, respectively. In contrast, chain A of aTriFlex_105 was produced at markedly lower levels resulting in an~5-fold excess of chain B and a reduced heterodimer content in cell culture supernatants (52.7%). Proteins were further purified to near homogeneity by gel filtration which resulted in elution of product containing equimolar amounts of chains A and B (Fig. 4B ) and improved heterodimer content to >92% for all preparations (Fig. 4C) . While a minor high molecular weight impurity of~7% of the total protein was detected in the preparation of aTriFlex_105, both aTriFlex_113 and aTriFlex_115 eluted as a single peak suggesting the presence of only heterodimerized molecular species. To determine whether introduction of scFv antibodies reduced aTriFlex stability relative to the ncDb core module, thermal unfolding was assessed by DSF analysis (Fig. 4D) . Unfolding of aTriFlex_105 and aTriFlex_115 was observed at lower temperatures of 49°C and 48°C, respectively, while aTriFlex_113 exhibited thermal stability (58.7°C) similar to ncDb. While the scFv antibodies used here were not engineered for high protein stability, the melting temperature of aTriFlex_113 suggested that incorporation of scFv antibodies in N-and C-terminal positions of chain A is in principle possible without affecting overall protein stability.
These data suggest that the previously established asymmetric anti-CD16A diabody motif may be used as a core module to enforce heterodimerization of two chains within the aTriFlex format to facilitate assembly into a trispecific NK cell-engaging antibody.
Selective binding to antigen double-positive cell lines
Functionality of the anti-CD16A core module used as a heterodimerization motif in aTriFlex antibodies was then tested to assess whether N-and C-terminal fusion of BCMA-and CD200-directed scFv domains resulted in altered CD16A binding affinity. For this, monovalent interaction kinetics of aTriFlex_105, aTriFlex_113 and aTriFlex_115 with recombinant, monomeric CD16A-mFc.67 was assessed by SPR analysis. All antibodies interacted with CD16A with similar interaction kinetics that were comparable with binding kinetics of anti-CD16A scFv, Db and ncDb, as previously measured (Fig. 5A) . Consequently, these data suggest functional integrity of the CD16A-directed paratopes in the context of aTriFlex antibodies.
To assess BCMA and CD200 binding of aTriFlex antibodies and their ability to selectively interact with cells co-expressing both antigens, antibodies were titrated on cell lines expressing BCMA or CD200 or both antigens to determine binding affinity and increases in avidity upon bivalent target cell interaction. Overall, interactions of all trispecifics with BCMA+ and CD200+ cell lines were weak and saturating conditions were not reached within the range of concentrations tested (Fig. 5B) . No binding could be detected when aTriFlex_113 was titrated on BCMA+ cells. Poor binding to antigen single-positive cell lines was consistent with the prior selection of target-specific domains based on low binding affinities to recombinant antigens in SPR analyses. No binding to antigen-negative cell lines was detected suggesting that the observed binding was not due to non-specific interactions. Strikingly, antibody binding was significantly improved when aTriFlex_105 and aTriFlex_115 were titrated on cell lines co-expressing BCMA and CD200 resulting in apparent affinities (K D ) of 12.7 nM and 51.1 nM, respectively. No apparent increase in avidity over CD200+ cells was observed for aTriFlex_113, which was consistent with the very poor binding observed on BCMA+ cells. Nevertheless, the data obtained with aTriFlex_105 and aTriFlex_115, in particular, suggest that marked gains in avidity can be achieved upon bivalent target cell interaction of trispecific antibodies despite the use of target antigen-specific antibody domains with low intrinsic affinity.
Dual-targeting of antigen double-positive cells with aTriFlex antibodies for selective NK cell-mediated lysis
Selective antibody binding to antigen double-positive cells may translate into preferential NK cell-mediated cytotoxicity towards BCMA+/CD200+ cells at lower antibody concentrations. To test this, aTriFlex-induced lysis of target cells by NK cells was assessed in in vitro cytotoxicity assays using BCMA+, CD200+, BCMA +/CD200+ or untransfected cell lines as target cells. While aTriFlex_113, consistent with cell binding experiments, did not induce target cell lysis more potently when both antigens were coexpressed, aTriFlex_105 and aTriFlex_115 induced half-maximal lysis (EC 50 ) of antigen double-positive cells at 9-fold (13.7pM) and 17-fold (259pM) lower antibody concentrations, respectively (Fig. 6A) . While this was in agreement with relative antibody selectivity previously observed in cell binding experiments, aTriFlex_115 also induced lysis of BCMA+ and CD200+ cells at high antibody concentrations, despite the low level of detectable binding. This may suggest that low affinity target cell binding in these experiments was sufficient to trigger effector cell activation. Similar results were obtained when NK cell activation by trispecific antibodies was assessed by quantifying CD69 surface expression on NK cells (Fig. 6B) . While high background CD69-positivity was consistently observed when NK cells were co-cultured with CHO cells due to the species difference, addition of aTriFlex_105 and aTriFlex_115 increased the frequency of CD69+ NK cells at lower concentrations on antigen double-positive cells compared with cells expressing only a single target antigen. No antibody-induced lysis and NK cell activation was observed when antigen-negative control cells were used as targets confirming the specificity of redirected NK cell lysis for BCMA-and/or CD200-expressing cells. Selectivity of aTriFlex_105 and aTriFlex_115 for BCMA+/CD200+ target cells was further confirmed by quantifying IFN-γ release subsequent to target cell lysis (Fig. 6C) . These data imply that developed trispecific antibodies could be used to increase selectivity of redirected NK cell lysis for tumors that co-express a select pair of target antigens.
Discussion
Retargeting cytotoxic effector cells through engagement of an activating receptor on T or NK cells and dual-targeting of tumors requires an antibody format that is at least trispecific. Various trispecific formats, such as tribodies, triplebodies and TriMabs have been described (Schoonjans et al., 2000; Kugler et al., 2010; Castoldi et al., 2012; Schubert et al., 2012) , however, none of these formats have been used to selectively engage effector cells via CD16A, the critical receptor mediating antibody-dependent cellular cytotoxicity (ADCC), without binding to other immune cell subtypes. Here we Fig. 4 Construct design, purification and thermal stability of trispecific, tetravalent aTriFlex antibodies. (A) Trispecific antibodies were designed as an assembly of two differently sized polypeptides, heterodimerized via interchain pairing of a central diabody-like motif comprised of two anti-CD16A (LSIV21) Fv units. Target-specific scFv domains, here anti-BCMA and anti-CD200, were fused to the N-and C-terminus of chain A, respectively. To enforce heterodimerization, anti-CD16A VL and VH chains were distributed onto different polypeptides. Antibody light (VL) and heavy chain (VH) variable domains and connecting peptide linkers are shown as rectangles and black bars, respectively. Superscript characters denote antibody specificities. (B) Purified aTriFlex_105, aTriFlex_113 and aTriFlex_115 were subjected to reducing SDS-PAGE followed by stain-free gel imaging. Arrowheads and upper-case characters mark the discretely migrating chains 'A' and 'B'. M, molecular weight marker. (C) Elution profiles of IMAC/pSEC-purified aTriFlex_105, aTriFlex_113 and aTriFlex_115 resolved on a calibrated Superdex 200 Increase 10/300 gel filtration column. Arrowheads mark elution volumes of molecular weight marker proteins with the indicated molecular weight (kDa) resolved under identical conditions. (D) DSF analysis of thermal unfolding of aTriFlex_105, aTriFlex_113 and aTriFlex_115. Melting temperatures are highlighted (arrowheads) sought to develop a novel trispecific antibody platform building on the modularity of the previously described Flexibody format and the beneficial properties of bivalent, high affinity targeting of NK cells using the CD16A-selective antibody LSIV21. Using an anti-CD16A core motif consisting of tandem VH or VL domains placed on two different polypeptides we demonstrate successful generation of heterodimeric trispecific antibodies. A similar domain arrangement has been described in other formats, including dual-variable domain (DVD)-Ig antibodies and the recently developed MATCH format confirming the feasibility of this approach to effect heterodimerization, although in the former constant heavy and light chain domains also contribute to correct chain association (Wu et al., 2007; Egan et al., 2017) . The anti-CD16A module developed here mediated efficient heterodimerization, was readily expressed and exhibited high protein stability at 2-8°C and 40°C suggesting good developability characteristics. The modularity of the developed format was confirmed by production of three aTriFlex antibodies incorporating different anti-BCMA and anti-CD200 scFvs all of which retained functionality with respect to antigen binding. While the used scFvs were neither selected based on stability nor stability- Table II . Target binding affinities used in aTriFlex antibodies as determined by SPR analysis engineered in the context of this work, at least one antibody, aTriFlex_113, also exhibited thermal stability comparable to the core motif suggesting modular assembly of aTriFlex antibodies is possible and may be a straightforward way to generate trispecifics incorporating different target specificities. Notably, expression titers of these antibodies at research stage and scale were also comparable with those typically seen for TandAbs suggesting that neither expression as a heterodimeric construct nor asymmetric assembly negatively affected overall yields and aTriFlex antibodies may be produced in sufficient amounts for clinical development. Dual-targeting of two surface antigens expressed on tumors with bispecific antibodies has been proposed as a strategy to increase tumor selectivity of antibody binding (Vallera et al., 2005; Robinson et al., 2008; Kugler et al., 2010) . Because of the widespread use of the term 'dual-targeting' to describe the activity of bispecific and trispecific antibodies with diverse mechanisms of action, it is worth contrasting the various approaches with the particular challenges posed by dual-targeting, as defined in the context of this study. A plethora of bispecific constructs have been designed to target two distinct epitopes on membrane-bound antigens or soluble mediators to mediate stimulatory or inhibitory effects or both (Kontermann, 2012) . In addition to comparatively simple 'two-in-one' antibodies in which both specificities operate independently, bispecifics have also been described whose therapeutic efficacy is enhanced by bivalent binding due to avidity (Dong et al., 2011; Croasdale et al., 2012; Moores et al., 2016; Schanzer et al., 2016) . For example, Zheng et al. (2016) recently described increased in vivo efficacy of a bispecific antibody targeting EGFR and c-Met when compared with combination treatment with the respective monovalent monoclonal antibodies. Here, increases in apparent binding affinity upon bispecific receptor engagement on the same cell were found to lower IC 50 values for EGFR and c-Met phosphorylation inhibition, both of which are intended effector mechanisms. Bispecific targeting approaches have also been described in which avidity effects are used to increase targeting selectivity by targeting a first antigen with reduced affinity to limit antibody binding to cells efficiently bound by a second high-affinity antibody with distinct specificity (Piccione et al., 2015) . This concept makes use of the phenomenon that target antigens are more efficiently bound than predicted based on their monovalent affinity when a first binding event targeting a different epitope has taken place and serves as an anchor on the cell surface, as recently described by Rhoden et al. (2016) . Again, however, the activity of the higher affinity functionality in this example is driven by its specificity and not dependent on avidity. In contrast to these examples, dual-targeting to increase selectivity of redirected effector cell lysis, as investigated in this study, utilizes two specificities to produce a single therapeutic effect, namely immune cell activation upon antigen double-positive target cell encounter. As such, it is heavily dependent on avidity to minimize interaction with singepositive cells and maximize binding to double-positive tumor cells in order to create a therapeutic window within which safe tumor cell targeting is possible. Activation of NK cell ADCC is triggered by the low affinity interaction between CD16A and IgG 1 bound to a target cell surface (Li et al., 2007) . Consequently, one may hypothesize that antibody domains with markedly lower affinity than that involved in CD16A-IgG 1 interactions are needed to avoid effector cell activation following monospecific target cell interaction. However, increases in apparent cell binding affinities upon conversion of monovalent to bivalent interactions are dependent on the involved intrinsic affinities, with greater increases possible with higher affinity antibodies (Crothers and Metzger, 1971) . Drastically reducing target antigen affinities is, therefore, expected to minimize gains in avidity and result in poor overall cell binding affinity and drug potency. We therefore hypothesized that a therapeutic window may be achieved by utilizing antibody domains that exhibit affinities comparable with or slightly higher than CD16A-IgG 1 interactions but lower than affinities typically used in bispecific NK cell engagers (Table II) . Using a BCMA and CD200-based model system, we observed significant increases in apparent cell binding affinity as determined by titrating dual-targeting aTriFlex antibodies on cells overexpressing BCMA and CD200. Although the avidity effect was less pronounced in functional assays, the observed binding selectivity translated into 17-fold increased in vitro potency of aTriFlex_115 towards double-positive cells. Consistent with the notion that low affinity interactions are sufficient to trigger NK cell activation, single-positive target cell lysis was also observed despite almost undetectable monovalent cell binding. It is possible that overexpression of BCMA and CD200 compensated for low binding affinity as variations in target antigen copy numbers are known to affect the potency of IgG antibodies to elicit ADCC in vitro (Lustig and Bianco, 1976) . Although both antigens were overexpressed (Fig. 6D) , similar copy numbers have been reported for cancerassociated antigens (Prang et al., 2005; Nestor et al., 2007; Ho-PunCheung et al., 2012) . It is also conceivable that high affinity and bivalent engagement of NK cells via CD16A results in increased sensitivity for target antigen and that significantly lower target affinities than used here are needed to prevent effector cell activation upon monovalent target cell binding using these constructs. Attempts by us to determine an affinity threshold for NK cell activation have so far been unsuccessful (data not shown) and more work is needed to better understand the affinities needed to reduce monovalent effector activation. Nevertheless, the data obtained here suggest that increased selectivity of NK cell cytotoxicity for antigen doublepositive cells can be achieved using the developed aTriFlex format.
Avidity of bivalent antibody binding to a target cell is largely dependent on the probability of conversion of monovalent to bivalent interactions. While intrinsic antibody affinity plays an important role, other factors, including antigen expression levels and epitope accessibility as well as antibody structure and relative geometries of paratopes and epitopes, are critical determinants and have been included in numerous mathematical models to describe bivalent target cell interactions (Crothers and Metzger, 1971; Kaufman and Jain, 1992; Muller et al., 1998; Doldan-Martelli et al., 2013; Harms et al., 2014; Chudasama et al., 2015) . These studies have highlighted that avidity is not an intrinsic antibody property but a function of the underlying biological system. Tumors are heterogeneous and antigen expression levels are variable in both healthy and malignant tissues, both within and between patients and this is expected to directly affect bispecific avidity and drug potency. Therefore, successful translation of dual-targeting, as defined here, into a clinical application will primarily depend on the identification of a suitable target pair that exhibits the necessary tumor-specific co-expression and eliminates or at least reduces these variables to allow consistent and predictable effector cell activation. An ideal scenario for dual-targeting, may be the use of a target pair that is either strongly co-localized or, preferably, heterodimerized within the cell membrane of a tumor cell and present only in low copy numbers on non-malignant cells expressing either antigen individually. Here, close proximity of target epitopes may result in high avidity that is independent of antigen expression levels. Dualtargeting of such pairs may ultimately provide the therapeutic window needed to safely target double-positive tumors.
The data presented here suggest the general feasibility of the dual-targeting concept using the developed CD16A-directed aTriFlex antibody format. In future work, it will be important to identify novel target antigen pairs with an underlying biology suitable to maximize the potential of dual-targeting and expand the use of this potent drug class into solid tumor indications.
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